Pandemic influenza vaccines and neuraminidase inhibitors: Efficacy and side effects

International Journal of Risk and Safety in Medicine

Volumn 23, Issue 2, 2011, Pages 65-71

  Bijl, D ^a  

^a Domus Medica   (Netherlands)

Author keywords

acetaminophen; Focetria ; Influenza A (H1N1); neuraminidase inhibitors; oseltamivir; pandemic; pandemic influenza vaccines; Pandemrix ; seasonal influenza; swine flu; swine influenza; zanamivir

Indexed keywords

INFLUENZA VACCINE; OSELTAMIVIR; SIALIDASE INHIBITOR; ZANAMIVIR;

ARTICLE; AUSTRALIA; AUTOMUTILATION; CONFUSION; DELIRIUM; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; ENCEPHALOMYELITIS; FATIGUE; FEVER; GUILLAIN BARRE SYNDROME; HEADACHE; HUMAN; INFLUENZA A; INFLUENZA A (H1N1); INFLUENZA B; INFLUENZA VIRUS A H1N1; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE REACTION; MALAISE; MYALGIA; NETHERLANDS; NEW ZEALAND; NONHUMAN; PANDEMIC; RISK BENEFIT ANALYSIS; SIDE EFFECT; SWEATING;

ADJUVANTS, IMMUNOLOGIC; ANTIVIRAL AGENTS; COMMUNICABLE DISEASE CONTROL; EXCIPIENTS; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; NEURAMINIDASE; OSELTAMIVIR; PANDEMICS; TREATMENT OUTCOME;

EID: 80051955276     PISSN: 09246479     EISSN: 18786847     Source Type: Journal    
DOI: 10.3233/JRS-2011-0521     Document Type: Article

References (25)

1. Informatorium Medicamentorium. Den Haag: KNMP, 2010.
2. I. Leroux-Roels, A. Borkowski, T. Vanwolleghem, M. Dramé, F Clement, E. Hons, et al., Antigen sparing and crossreactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: A randomised controlled trial, Lancet 370 (2007), 580-589.
3. Productinformation pandemic influenzavaccin (Focetria®). Available at: Http://www.ema.europa.eu, human medicines, EPAR's.
4. Productinformation pandemic influenzavaccin (Pandemrix®). Available at: Http://www.ema.europa.eu, human medicines, EPAR's.
5. A.J. Wakefield, S.H. Murch, A. Anthony, J. Linnell, D.M. Casson, M. Malik, et al., Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, Lancet 351 (1998), 637-641.
6. Retraction-Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children, Lancet 375 (2010), 445.
7. S.K. Parker, B. Schwartz, J. Todd and L.K. Pickering, Thiomersal-containing vaccines and autistic spectrum disorder: A critical review of published original data, Pediatrics 114 (2004), 793-804.
8. EMEA Public statement on thiomersal in vaccines for human use - recent evidence supports safety of thiomersalcontaining vaccines. Available at: Http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/ WC500003904.pdf.
9. M.E. Greenberg, M.H. Lai, G.F. Hartel, C.H. Wichems, C. Gittleson, J. Bennet, et al., Response to a monovalent 2009 influenza A (H1N1) vaccine, N Engl J Med 361 (2009), 2405-2413.
10. F.-C. Zhu, H. Wang, H.-H. Fang, J.G. Yang, X.J. Lin, X.-F. Liang, et al., A novel influenza A (H1N1) vaccine in various age groups, N Engl J Med 361 (2009), 2414-2423.
11. T.W. Clark, M. Pareek, K. Hoschler, H. Dillon, K.G. Nicholson, N. Groth, et al., Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine, N Engl J Med 361 (2009), 2424-2435.
12. J.F. Bishop, M.P. Murnane and R. Owen, Australia's winter with the 2009 pandemic influenza A (H1N1) virus, N Engl J Med 361 (2009), 2591-2594.
13. A.M. Presanis and D. de Angelis, The New York city swine flu investigation team, A. Hagy, C Reed, S. Riley, B.S. Cooper, et al., The severity of pandemic H1N1 influenza in the United States, from april to july 2009: A Bayesian analysis, PLoS Med 6 (2009), e1000207.
14. L.J. Donaldson, P.D. Rutter, B.M. Ellis, F.E.C. Greaves, O.T. Mytton, R.G. Pebody, et al., Mortality from pandemic A/H1N1 2009 influenza in England: Public health surveillance study, BMJ 339 (2009), b5213.
15. Statement by Dr. Keiji Fukuda on behalf of WHO at the Council of Europe hearing on pandemic (H1N1) 2009. WHO; 26 januari 2010. Available at: Http://www.who.int/csr/disease/swineflu/coe-hearing/en/print.html.
16. J. de Jong, Oseltamivir (Tamiflu®), preventie en behandeling influenza. Geneesmiddelenbulletin 39 (2005), 133-135.Available at: Http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Oseltamivir-Tamiflu- preventie-en-behandeling-influenza.htm.
17. T.O. Jefferson, V. Demicheli, C. di Pietrantonj, M. Jones and D. Rivetti, Neuraminidase inhibitors for preventing and treating influenza in healthy adults, Cochrane Database Syst Rev 3 (2006), CD001265.
18. T. Jefferson, M. Jones, P. Doshi and C. del Mar, Neuraminidase inhibitors for preventing and treating influenza in healthy adults: Systematic review and meta-analysis, BMJ 339 (2009), b5106.
19. D. Cohen, Complications: Tracking down the data on oseltamivir, BMJ 339 (2009), 1342-1347.
20. P. Doshi, Neuraminidase inhibitors: The story behind the Cochrane review, BMJ 339 (2009), 1348-1351.
21. L. Kaiser, C.Wat, T. Mills, P. Mahoney, P.Ward and F. Hayden, Impact of oseltamivir treatment on influenza-related lower respiratory tract complications and hospitalizations, Arch Intern Med 163 (2003), 1667-1672.
22. Anonymous, Wat is gevaarlijker voor uw gezondheid: Griep of Tamiflu (oseltamivir)? Geneesmiddelenbulletin 41 (2007), 48.Available at: Http://gebu.artsennet.nl/Archief/Tijdschriftartikel/Wat-is-gevaarlijker-voor-uw- gezondheid-griepof- Tamiflu-oseltamivir.htm.
23. D. Bijl, Bijwerkingen oseltamivir (Tamiflu®). Geneesmiddelenbulletin 41 (2007), 43.Available at: Http://gebu.artsennet.nl/ Archief/ Tijdschriftartikel/Bijwerkingen-oseltamivir-Tamiflu.htm.
24. R. Hama, Fatal neuropsychiatric adverse reactions to oseltamivir: Case series and overview of causal relationships, Int J Risk Safety Med 20 (2008), 5-36.
25. EMEA recommendations on extension of shelf life for TAMIFLU. EMA; 8 mei 2009. Available at: Http://www.ema. europa.eu/humandocs/PDFs/EPAR/tamiflu/ 28497109 en.pdf.